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ANALYSIS OF THE HLA-DQ ALLELES IN THE TYPE 1 DIABETES POPULATION 
AND THEIR UNAFFECTED FIRST DEGREE RELATIVES 
Brandy Marie Smolnik, M.S. 
University of Pittsburgh, 2007
 
Type 1 diabetes mellitus (T1D) is a disease of major public health concern as it is one of 
the most common diseases of childhood and costs millions of dollars in health care each year in 
the U.S. T1D is an autoimmune disease and is caused by multiple factors including genetics, 
autoimmunity, and environment. The genetics of T1D is complex as there are multiple genes 
thought to play a role in its susceptibility, with the best defined risks associated with the HLA-
DQ molecule. This study analyzes the role of the DQ molecule in 265 diabetic children and 1000 
unaffected first degree relatives in order to further support the current literature of the presence 
of specific DQ alleles and haplotypes with a large representative sample from the U.S. 
In the diabetic probands, the analysis was supported by the previous literatures for the 
presence of non-Asp 57 alleles but not for the presence of the DQ2 and DQ8 haplotypes. In this 
study, 94.14% (96.65% including the DR2 group) have at least one non-Asp allele with a 
breakdown of 30.54% as non-Asp/Asp (33.05% including DR2) and 63.60% with non-Asp/non-
Asp, and 6% Asp/Asp. The distribution of the DQ2 and DQ8 haplotypes includes, 78.63% 
possessing DQ2 and/or DQ8 haplotypes with 6.49% as DQ2 homozygotes (DQ2/DQ2), 4.96% 
as DQ8 homozygotes (DQ8/DQ8), and 16.79% as DQ2/DQ8 heterozygotes. These figures are 
only slightly higher when looking at the Caucasians or the individuals with younger ages of 
onset. These unexpected results may be the result of clinical or ethnic variability in the 
population, however further investigation is warranted. 
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While there is limited information available of the non-Asp alleles and DQ2 and DQ 
haplotypes for first degree relatives, the results in the study seem to be supported both by 
previous studies and on the risks associated with each haplotype. Results show that 33.59% non-
Asp/non-Asp, 58.2% Asp/non-Asp (with 14.55% of these individuals non-Asp/0602 
specifically), and 8.21% Asp/Asp.  In the DQ2 and DQ8 analysis 68.34% had DQ2 and/or DQ8 
haplotypes, with 31.94% as DQ2 homozygotes or heterozygotes, 30.11% were either DQ8 
homozygous or heterozygous, and 6.31% were DQ2/DQ8 heterozygotes. 
 
 v 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ..................................................................................................... XII 
1.0 INTRODUCTION........................................................................................................ 1 
1.1 PURPOSE OF THE STUDY .............................................................................. 1 
2.0 BACKGROUND AND SIGNIFICANCE .................................................................. 2 
2.1 DIABETES OVERVIEW ................................................................................... 2 
2.2 PATHOPHYSIOLOGY...................................................................................... 3 
2.3 IMMUNE SYSTEM ............................................................................................ 4 
2.4 GENETICS........................................................................................................... 6 
2.4.1 Genetic Susceptibility ................................................................................... 6 
2.4.2 HLA and DQ ................................................................................................. 8 
2.4.3 Other Genes of Interest .............................................................................. 16 
2.5 ENVIRONMENTAL FACTORS..................................................................... 19 
2.6 AUTOANTIBODIES......................................................................................... 21 
2.7 THE SSOP METHOD....................................................................................... 24 
2.8 SPECIFIC AIMS ............................................................................................... 25 
3.0 MATERIALS AND METHODS .............................................................................. 27 
3.1 STUDY POPULATION .................................................................................... 27 
3.2 HLA-DQ TYPING BY REVERSE SSOP ....................................................... 28 
 vi 
3.3 DQ RISK ALLELES AND HAPLOTYPE STRATIFICATION.................. 29 
3.4 STATISTICAL METHODS............................................................................. 30 
4.0 RESULTS ................................................................................................................... 31 
4.1 PROBANDS AND FIRST DEGREE RELATIVES (FDRS)......................... 31 
4.1.1 Demographics.............................................................................................. 31 
4.1.2 Non-Asp 57 Analysis for Probands and FDRs ......................................... 32 
4.1.3 DQ2 and DQ8 Analysis for Probands and FDRs..................................... 37 
5.0 DISCUSSION ............................................................................................................. 42 
5.1 PROBANDS ....................................................................................................... 42 
5.1.1 Non-Asp 57 Analysis of Probands Compared to Probands in the 
Literature .................................................................................................................... 42 
5.1.2 Non-Asp 57 Analysis of Probands Compared to Unaffected Individuals
 46 
5.1.3 DQ2 and DQ8 Distribution of Probands .................................................. 48 
5.2 FIRST DEGREE RELATIVES RESULTS .................................................... 51 
5.2.1 Non-Asp 57 Analysis of FDRs.................................................................... 51 
5.2.2 DQ2 and DQ8 Analysis of FDRs................................................................ 54 
5.2.3 Future Directions ........................................................................................ 55 
6.0 CONCLUSIONS ........................................................................................................ 56 
BIBLIOGRAPHY....................................................................................................................... 59 
 vii 
 LIST OF TABLES 
 
Table 1: Empiric Risk of Type 1 Diabetes Mellitus. Modified with permission from Pietropaolo, 
M. and D. Le Roith, Pathogenesis of diabetes: our current understanding. Clin Cornerstone, 
2001. 4(2): p. 1-16.[8]..................................................................................................................... 7 
Table 2: Effect of Human Leukocyte Antigen Alleles on Susceptibility to IDDM. Used with 
permission from Dr. Massimo Pietropaolo found in Pietropaolo, M. and D. Le Roith, 
Pathogenesis of diabetes: our current understanding. Clin Cornerstone, 2001. 4(2): p. 1-16. [8]
....................................................................................................................................................... 15 
Table 3: Summary of Human IDDM Susceptibility Loci. Used with permission from Dr. 
Massimo Pietropaolo. Table from Pietropaolo, M. and D. Le Roith, Pathogenesis of diabetes: 
our current understanding. Clin Cornerstone, 2001. 4(2): p. 1-16. [8]........................................ 16 
Table 4: Gender Distribution for Probands and FDRs.................................................................. 31 
Table 5: Race Distribution for Probands and First Degree Relatives (FDRs).............................. 32 
Table 6: Ethnicity Distribution for Probands and First Degree Relatives (FDRs) ....................... 32 
Table 7: Non-Asp Analysis of Probands and FDRs ..................................................................... 33 
Table 8: Non-Asp 57 Analysis of Probands and FDRs, by Relationship ..................................... 34 
Table 9: Non-Asp 57 Analysis of Caucasian Probands and FDRs............................................... 35 
Table 10: Non-Asp 57 Analysis of Caucasian Probands and FDRs, by Relationship.................. 36 
 viii 
Table 11: DQ2 and DQ8 Analysis of Probands and FDRs........................................................... 38 
Table 12: DQ2 and DQ8 Analysis of Probands and FDRs, by Relationship ............................... 39 
Table 13: DQ2 and DQ8 Analysis of Caucasian Probands and FDRs ......................................... 40 
Table 14: DQ2 and DQ8 Analysis of Caucasian Probands and FDRs, by Relationship .............. 41 
Table 15: Comparison of Non-Asp Status in Caucasians to Previous Literature on Diabetics.... 43 
Table 16: Comparison of Non-Asp Status for Caucasian Probands vs. FDRs ............................. 46 
Table 17: Comparison of Non-Asp Status in Caucasian Probands and General Population in the 
Literature....................................................................................................................................... 47 
Table 18: Caucasian Analysis: Probands vs. FDRs vs. General Population ................................ 48 
Table 19: Comparison of DQ2 (DR3) and DQ8 (DR4) Haplotypes in Diabetic Probands in the 
Study vs. Morel et al ..................................................................................................................... 50 
Table 20: Approximate Non-Asp Status of Caucasian Probands vs. FDRs vs. Controls in Dorman 
et al................................................................................................................................................ 51 
Table 21: Approximate Percentages of Non-Asp Status of Caucasian Probands vs. Siblings vs. 
Parents vs. Controls in Dorman et al. ........................................................................................... 53 
 ix 
LIST OF FIGURES 
 
Figure 1: Annual Incidence of Type 1 Diabetes per 100,000 by Country  [5] ............................... 3 
Figure 2: Antigen uptake and presentation by antigen presenting cells (APC) with peptide in the 
groove of a MHC class II molecule to a CD4+ T cell. Used with permission from Dr. Massimo 
Pietropaolo.  Figure taken from Pietropaolo, M. and D. Le Roith, Pathogenesis of diabetes: our 
current understanding. Clin Cornerstone, 2001. 4(2): p. 1-16 [8]. ................................................ 5 
Figure 3: The HLA Complex. Used with permission from Eisenbarth GS, Lafferty KJ, eds. Type 
1 Diabetes: Molecular, Cellular and Clinical Immunology. New York, Oxford: Oxford University 
Press; 1996:3–17. Web site [9]....................................................................................................... 8 
Figure 4: HLA-DQ combining site. Used with permission from Trucco, M., To be or not to be 
Asp 57, that is the question. Diabetes Care, 1992. 15(5): p. 705-15. [12].................................... 12 
Figure 5: Antigen Presenting Via the HLA Molecule. Used with permission from Trucco, M., To 
be or not to be Asp 57, that is the question. Diabetes Care, 1992. 15(5): p. 705-15. [12]............ 13 
Figure 6: Risk of diabetes in First Degree Relatives in the Presence of Multiple Markers. Used 
with permission by Dr. Dorothy J. Becker found in Pietropaolo, M., et al., Progression to 
insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-
risk haplotypes. Diabetologia, 2002. 45(1): p. 66-76.  [26].......................................................... 23 
 x 
Figure 7: Risk of Diabetes for First Degree Relatives in the Presence of Multiple Autoantibodies 
(GAD65, Insulin, and IA2) [21] ................................................................................................... 24 
 xi 
ACKNOWLEDGEMENTS 
 
I would like to first express my sincere gratitude to my thesis advisor, Dr. Dorothy Becker. 
Thank you so much for the opportunity to work with and learn from you and your research team. 
I appreciate all of the time and resources you were able to extend to me along the way. 
I would also like to thank the other members of my thesis committee, Ms. Elizabeth 
Gettig, M.S, CGC and Dr. Vincent Arena. I am truly grateful for all of the time and effort you 
provided as well as your encouragement and suggestions. 
In addition, I would like to express my thanks to Dr. Ingrid Libman in assisting me in the  
investigation of some of my results; Ms. Lynn Nichol for all of her help in explaining the 
laboratory methods; Dr. Massimo Trucco for providing his insight; Dr. Eleanor Feingold for 
statistical assistance; my other director Dr. Robin E. Grubs for her mentoring and support; Ms. 
Carrie Blout, MS who provided some insight and resources from her prior experience in diabetes 
research; and the rest of Dr. Becker’s research team: Karen Riley, Linda Freytag, Leann Bullian, 
Kelli Delallo, Kym Smith, Maribel Cedillo, and Kelly Brewer for their general encouragement, 
support, and patience during this past year and half. 
I would also like to thank my parents, friends, and classmates for all of their support 
throughout this time. I appreciate the ear to listen, the shoulder to lean on, and the wisdom in 
your words. It wouldn’t have been the same without you. 
 xii 
1.0  INTRODUCTION 
1.1 PURPOSE OF THE STUDY 
Type 1 diabetes mellitus (T1DM) is a disease of major public health concern and it is believed 
that there are multiple genetic, autoimmune, and environmental factors that play a role in its 
onset. The genetics of T1DM is complex as there are many different genes thought to play a role 
in susceptibility to developing T1DM. Making up 50-60% of the genetic risk of T1D, one of the 
best studied is the HLA gene class II molecules DQ. The purpose of this study is to examine the 
genetic distribution related to DQ in the T1DM population and their unaffected first degree 
relatives enrolled in the Etiology and Epidemiology of Insulin Dependent Diabetes study through 
Children’s Hospital of Pittsburgh. This analysis is to determine if this study population has 
similar results to previous studies to further serve as evidence in the role of DQ and T1DM 
susceptibility.  
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 DIABETES OVERVIEW 
Type 1 diabetes (T1D), formerly known as juvenile diabetes due to its common onset during 
childhood or adolescence is also known as Type 1a diabetes or Insulin Dependent Diabetes 
Mellitus (IDDM). Type 1 diabetes is an autoimmune disorder characterized by the T-cell 
mediated destruction of the β cells of islets of Langerhans in the pancreas. The pancreatic β cells 
are responsible for the production of the hormone insulin in the body. Therefore, destruction of 
the β cells leads to absolute insulin deficiency resulting in chronic hyperglycemia [1]. As a 
result, individuals with T1D require daily exogenous insulin treatment as well as frequent 
surveillance of blood glucose levels. 
It is estimated that over 20.8 million Americans have diabetes, with only 14.2 million 
actually being diagnosed. Of these individuals, 90-95% have what is known as type 2 diabetes, a 
non-autoimmune disease of insulin resistance that typically occurs in adulthood. The other 5-
10% are affected with type 1 diabetes, with 1 in 400 adolescents being diagnosed with T1D[2]. 
Diabetes in general thus has huge impact on public health. The annual cost of T1D exceeds 14 
billion dollars in Canada and about 10 times more in the United States, figuring in consumption 
of one in seven health care dollars [3].  
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The peak incidence of T1D is 11 years, but new cases occur almost as frequently in 
adulthood. T1D is more common in whites than blacks and differences in incidences vary across 
the world (Figure 1). The highest annual incidence of type 1 diabetes mellitus is found in Finland 
with 45 cases per 100,000, 30 per 100,000 in Sardinia, and the lowest is found in Korea with < 1 
per 100,000. The incidence of type 1 diabetes is increasing at a rate of approximately 3% a year 
and the expected annual incidence is expected to exceed 30 per 100,000 by 2010[4]. 
\
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Figure 1: Annual Incidence of Type 1 Diabetes per 100,000 by Country  [5] 
 
2.2 PATHOPHYSIOLOGY 
As other autoimmune diseases, T1D is believed to result from a combination of genetic, 
autoimmune, and environmental factors. The exact mechanism in humans has still yet to be 
elucidated but much has been discovered in the basic pathogenesis in the development in T1D. 
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The process includes specific haplotypes/genotypes establish a susceptibility to develop T1D, 
environmental factors that can either initiate an immune response against the β cells or that alter 
the structure of the β cells which then results in an immune response and destruction against the 
β cells, β cell infiltration by mononuclear immune cells (dendritic cells, macrophages, T-cells, 
etc) which directly contribute to β cell destruction, and then the subsequent development of T1D 
[6]. The specific process of the self-reactive T cells accumulating and targeting the β cells, where 
they expand and become increasingly efficient β cell destruction is known as progressive 
prediabetes. Prediabetes is believed to occur in individuals early in life and the process to 
diabetes development varies in length among individuals both within and across families [3]. 
While not the focus of this thesis, much work has been done and is still attempting to determine 
why some individuals develop T1D at a very young age and others in adulthood. 
 
 
2.3 IMMUNE SYSTEM 
The immune system is based on the basic concept of being able to recognize molecules in the 
body as either “self” or “nonself”. Antigens are foreign particles, such as viruses or microbes, 
which contain markers that indicate to the immune system as “nonself”. This initiates an immune 
response where antibodies are made. When the immune system mistakes “self” molecules as 
“nonself” and an immune response occurs it is called an autoimmune response. The immune 
system is made of several organs, including the thymus which is responsible for the maturation 
of the T lymphocytes, also known as T cells. The T cells contain receptors on their surfaces (T 
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cell receptors) that recognize antigens on the surfaces of infected cells. Helper T cells are 
responsible for directing immune responses via cell communication. Through this, antibody 
production by the B cells is stimulated, phagocytes are involved, and other T cells are activated. 
Cytotoxic lymphocyte T cells directly attack cells carrying foreign or altered molecules [7]. T 
cell recognition of exogenous antigens is performed through a process by which the antigens are 
cleaved into peptides and then coupled to the human leukocyte antigen (HLA) class II molecules 
of the major histocompatibility complex (MHC). Then, the class II molecules present the 
antigens to the cell surface of antigen presenting cells for CD4-positive T cell recognition. This 
process is illustrated in Figure 2.  
 
 
Figure 2: Antigen uptake and presentation by antigen presenting cells (APC) with peptide in the 
groove of a MHC class II molecule to a CD4+ T cell. Used with permission from Dr. Massimo Pietropaolo.  
Figure taken from Pietropaolo, M. and D. Le Roith, Pathogenesis of diabetes: our current understanding. Clin 
Cornerstone, 2001. 4(2): p. 1-16 [8]. 
 
 5 
Conversely, endogenous antigens, such as self proteins, are cleaved and transported into 
the endoplasmic reticulum of the cell while coupled to class I MHC molecules. Then, they are 
presented on the cell surface for recognition by CD8 T cells. T cells can only respond to peptide 
antigens that are bound to class I or class II MHC molecules on antigen presenting cells (APCs). 
APCs include macrophages, B cells, and dendritic cells and are responsible for pathogen and 
other particle clearance. This is accomplished through endocytosis in which the antigens are 
reduced to smaller peptides and are then presented in the groove of the MHC molecule. 
The HLA class II genes act as immune response genes and contain highly polymorphic 
regions which are inherited in a Mendelian manner. Each individual’s specific amino acid 
sequence determines which antigens they can respond to as each amino acid is responsible for 
binding and presenting specific antigens. During the development of the immune system, the 
potential exists for a response to almost every foreign antigen as well as every self-antigen. 
Therefore, depending on which sequences are inherited it can also determine which autoimmune 
diseases an individual is more susceptible to. Further details of the MHC and HLA class II genes 
are discussed in section 2.4.2 [9]. 
2.4 GENETICS 
2.4.1 Genetic Susceptibility 
The belief that there is a genetic susceptibility to T1D was initially based on observations of 
diabetes-clustering in families and the indication that relatives of T1D probands appeared to have 
an increased risk to develop the disease. Among Caucasians in North America, the risk for first 
 6 
degree relatives ranges from 1% to 15%, dependent on the specific relationship (Table 1), 
compared with 0.12% in the general population. 
 
Table 1: Empiric Risk of Type 1 Diabetes Mellitus. Modified with permission from Pietropaolo, M. 
and D. Le Roith, Pathogenesis of diabetes: our current understanding. Clin Cornerstone, 2001. 4(2): p. 1-16.[8] 
 
Group at Risk Empiric Risk (%) 
First-degree relatives of T1DM probands* 5–7‡  
Individuals without relatives with T1DM* <1 
Children of affected father† 6 
Children of affected mother†  2 
*Estimates for North American white populations.
‡Estimates for Scandinavian populations.
†1% to 15% range depending on the populations. 
 
 
These empirical risks illustrate that while there is a genetic susceptibility to developing 
T1D, it is not inherited in a Mendelian fashion. In fact, 80-90% of individuals with T1D have no 
family history of the disease. The differences seen in risk estimates for first degree relatives are 
believed to vary due to the concept of haplotype sharing. Individuals have two copies of each of 
their chromosomes, one inherited from each parent. They therefore have two copies of each of 
their genes, alleles, and so forth. A haplotype is the combination of alleles found on one of the 
chromosomes. Parents and their offspring can at maximum share only one haplotype whereas 
siblings have the possibility of sharing both haplotypes. Therefore, this supports the increased 
risk of siblings of diabetic probands versus children of diabetic probands [10]. 
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2.4.2 HLA and DQ 
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Figure 3: The HLA Complex. Used with permission from Eisenbarth GS, Lafferty KJ, eds. Type 1 
Diabetes: Molecular, Cellular and Clinical Immunology. New York, Oxford: Oxford University Press; 1996:3–
17. Web site [9] 
 
In the mid 1970s, the Human Leukocyte Antigen (HLA) genes, were the first to be identified as 
diabetes susceptibility genes and have since been shown to play the largest role in a genetically 
heterogenous disease, comprising approximately 50% of the genetic risk [8, 11]. Thus, the HLA 
genes are known as IDDM1. The HLA genes are located within the major histocompatibility 
complex (MHC) which is located on the short arm of chromosome 6. The MHC is divided into 
three subregions, class I, class II, and class III. The class III genes encode a range of molecules 
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that are not related to immune function. The class I genes are responsible for α peptide chains 
which associate with β2 microglobulin to form the class I molecules. The class I molecules play 
a role in the restriction of cytotoxic T cell activity and are expressed on all nucleated cells’ 
surfaces. The molecules bind endogenous antigen-derived peptide fragments. Then, the 
fragments are presented by the molecules for CD8 positive T cell receptor recognition.  
The class II locus is comprised of one A gene and one B gene and are the closest to the 
centromere on chromosome 6. The A gene encodes for an α peptide chain and the B gene 
encodes for a β peptide chain, which together form a heterodimer that is the class II molecules. 
The class II molecules are termed DR, DQ, and DP, with DR and DQ being in high linkage 
disequilibrium (LD)[6].  
Initially it was the class I alleles, in particular, that were associated with T1D due to their 
cosegregation in families. However, these alleles were also found to be fairly common and did 
not offer a very high relative risk ratio. Also, these observations were made before the class II 
molecules had been discovered. Once serological identification of the class II molecules was 
possible, it was determined that they were much better genetic markers in evaluating the risk for 
T1D. Following this, between 1979 and 1981, several groups identified the DR3 and DR4 alleles 
conferred the highest susceptibility and the DR2 alleles provided the highest resistance to the 
disease. These associations were subsequently confirmed in 1984 at the IX International 
Histocompatibility Workshop as studies showed that >90% of individuals with T1D were either 
DR3 or DR4. Of these individuals, only 7.2% were DR3/DR3 homozygous and 7.9% were 
DR4/DR4 homozygous, but 33.6% were DR3/DR4 heterozygous. Being heterozygous for 
DR3/DR4 was thus the highest genetic risk factor which initially did not make sense. To explain 
this situation, Svejgaard et al proposed that one of the α chains in the DR molecule is paired in 
 9 
trans, with each one coming from a different copy of the two chromosomes, with one of the β 
chains forming a hybrid molecule. In this formation, the DR3/DR4 heterozygous molecule would 
be highly involved in presenting antigens to the T cells, initiating an autoimmune process. 
However, this hypothesis was rejected when it was later determined that actually in the DR 
molecule a polymorphic β chain pairs with a monomorphic α chain. Since the α chain is the same 
on both copies of the chromosome, there is no real difference between a cis versus trans 
formation.  
Around 1987, as restriction fragment length polymorphism (RFLP) technology began to 
be used in the labs, it became more and more evident that the DQ molecule was more often 
involved in the risk to develop T1D. This also revived and supported the prior hypothesis of a 
hybrid molecule facilitating an autoimmune process, as both the α and β chains of the DQ 
molecule are polymorphic. The DQ molecule as the indicator for diabetes risk was not fully 
accepted at first, however further studies lent more support including the nonobese diabetic 
(NOD) mouse which spontaneously develops autoimmune diabetes and only has what is the 
human DQ complement for a class II molecule and it is negative for what is the human DR 
complement. Of particular interest, the only difference between the DQ-equivalent molecule in 
nonobese normal (NON) mice and NOD mice is that at position 57 of the β chain aspartic acid is 
exchanged for serine in the NOD mice. The relevance of this was subsequently determined when 
Bjorkman et al. determined the structure of the crystallized HLA-A2 molecule. The structure 
supported the role of the HLA molecule presenting a processed antigen (i.e. antigenic peptide) to 
the appropriate T cells. For example, the DQ molecule contains a groove where the processed 
antigen lodges for T cell presentation (Figures 4 and 5: the asterisks (*) in Figure 4 indicates 
residue 52 of the α-chain and 57 of the β-chain). Looking into this groove is residue 57 and is 
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therefore in a position to interact with the process antigen. Considering the prior observations in 
the NOD and NON mouse and the differing amino acids in position 57, it was hypothesized that 
an amino acid substitution is critical in mediating the autoimmune reaction via its effect on the 
lodging of the antigenic peptide in the groove. With the advent of polymerase chain reaction 
(PCR) techniques and sequence specific oligonucleotide probes, they were able to see the 
variations in codon 57 in both diabetic and non-diabetic individuals. By the end of 1987, 
multiple studies showed a strong correlation between having a non-charged amino acid such as 
alanine, valine, or serine at codon 57 in diabetic patients instead of having aspartic acid as was 
most often seen in non-diabetic patients. Therefore, being “non-Asp” or “Asp” is describing 
whether an allele on the β-chain encodes for aspartic acid to be present at position 57 (Asp) or a 
different non-charged amino acid (non-Asp). How this was explained was that the presence of 
Asp 57 inhibits “perfect” lodging of an antigenic peptide into the groove, which makes it less 
likely to be presented to the T cell and initiate an autoimmune process, whereas the absence of 
Asp 57 would make it more likely for the peptide to lodge into the groove allowing this 
diabetogenic molecule to be presented for recognition [12]. 
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Figure 4: HLA-DQ combining site. Used with permission from Trucco, M., To be or not to be Asp 57, 
that is the question. Diabetes Care, 1992. 15(5): p. 705-15. [12] 
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Figure 5: Antigen Presenting Via the HLA Molecule. Used with permission from Trucco, M., To be 
or not to be Asp 57, that is the question. Diabetes Care, 1992. 15(5): p. 705-15. [12] 
 
As DQ became accepted as the HLA molecule involved with the genetic predisposition 
for T1D, the earlier associations of DR3/DR3, DR4/DR4, and DR3/DR4 with the highest level of 
diabetes susceptibility was revisited. With the DR and DQ molecules in such high linkage 
disequilibrium it was determined that it was really the DQ haplotypes of DQA1*0501-
DQB1*0201 (LD with DR3) and DQA1*0301-DQB1*0302 (LD with DR4) that were involved. 
Therefore, the genotype with conferring the largest risk of T1D is the DQA1*0501-
DQB1*0201/DQA1*0301-DQB1*0302 heterozygote. Again this heterozygous “disadvantage” is 
explained by the formation of a hybrid molecule that is particularly diabetogenic due to the trans 
formation of the alleles and the resulting effect on antigen binding and presentation [13].  
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In addition, Khalil et al discovered in 1990 that diabetes susceptibility could be further 
defined by the presence or absence of arginine at position 52 on the α chain in combination with 
the presence or absence of Asp 57 on the β chain of the DQ molecule. The combination with the 
maximum susceptibility to the disease is arginine at position 52 and non-Asp at position 57, and 
vice versa for the maximum resistance. As these two positions are located on the opposite ends 
of the groove-containing space, it can be explained that both positions 52 and 57 and their amino 
acids are in a prime physical location, in addition to the reactions between a neutral non-Asp 
amino acid and arginine, to affect the presentation of an antigen to the T cell [14]. DQ2 and DQ8 
are indeed a particular combination of alleles where one codes for Arg at position 52 on the 
alpha chain and the other for non-Asp at position 57 on the beta chain. 
Today, the DQ2 and DQ8 haplotypes and genotype are still consistently shown to cause 
an increased genetic risk in developing T1D. Both as a group and individually this is true, 
however when looking at them within the group the order of risk from highest to lowest is 
DQ2/DQ8 (~1:15), DQ8/DQ8 (~1:60-200), DQ8/X (~1:60-200), DQ2/DQ2 (~1:60-200), and 
DQ2/X (~1:300) (where “X” indicates the presence of any other alpha and beta allele with the 
exception of DQB1*0602). In addition, DQA1*0102/DQB1*0602/DRB1*1501 (DR2) haplotype 
has shown a high protective effect against the development of T1D, even in the presence of 
autoantibodies [5, 15].  
It had been long observed that monozygotic twin concordance for T1D was not 100%, 
with estimates ranging from 20 to <40% [16, 17]. This can be explained genetically by the fact 
that the genes that encode the class II molecules are often subject to somatic rearrangement. 
Also, with the PCR based methods, HLA typing was performed of multiple populations with 
differing incidences of T1D. Once genotype frequencies of non-Asp 57 was determined, it was 
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shown to correlate with the population’s corresponding disease incidence thus identifying 
genetic differences as the primary reason for incidence differences, with the exception of 
Japanese populations which suggest a different role of non-Asp 57 in this population or 
discrepancies in study designs [12]. Studies have shown DQ associated susceptibility is only 
accurate for populations where the disease is common, whereas in populations where the disease 
is rare as in Asians the same associations are not seen [13]. 
The following is a table with known DQ alleles and their effect on susceptibility to T1D. 
The last column lists the associated DR class that is known by linkage disequilibrium. 
 
Table 2: Effect of Human Leukocyte Antigen Alleles on Susceptibility to IDDM. Used with 
permission from Dr. Massimo Pietropaolo found in Pietropaolo, M. and D. Le Roith, Pathogenesis of diabetes: 
our current understanding. Clin Cornerstone, 2001. 4(2): p. 1-16. [8] 
 
DQ Alleles Effect Associated DR Class 
A1*0301, B1*0302 Susceptible DR4 
A1*0501, B1*0201 Susceptible DR3 
A1*0101, B1*0501 Susceptible DR1 
A1*0301, B1*0201                  
Susceptible(AfricanAmericans) 
DR7 
A1*0102, B1*0502 Susceptible(Sardinians) DR2 (DR16) 
A1*0301, B1*0303 Susceptible (Japanese) DR4 
A1*0301, B1*0303 Susceptible (Japanese) DR9 
A1*0102, B1*0602 Protective DR2 (DR15) 
A1*0501, B1*0301 Protective DR5 
? B1*0600 Neutral DR6 
A1*0201, B1*0201 Neutral DR7 
A1*0301, B1*0303 Neutral DR4 
A1*0301, B1*0301 Neutral DR4 
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2.4.3 Other Genes of Interest 
There are many different genetic loci, mostly detected by genome-wide scans, associated with 
T1D risk. However, no other loci have showed a stronger effect or with such reproducibility as 
the HLA genes. Table 3 lists the known susceptibility loci as of 2001.  
 
Table 3: Summary of Human IDDM Susceptibility Loci. Used with permission from Dr. Massimo 
Pietropaolo. Table from Pietropaolo, M. and D. Le Roith, Pathogenesis of diabetes: our current understanding. 
Clin Cornerstone, 2001. 4(2): p. 1-16. [8] 
 
Chromosome Locus 
Linkage Status According to Kruglyak & 
Lander] 
6p21 IDDM1; HLA-DQB Confirmed 
11p15.5 IDDM2; INS 5 VNTR Confirmed 
15q26 IDDM3; IGF1R Suggestive (P < .001, MLS > 2.2) 
11q13 IDDM4; FGF3 Confirmed (P < 2.2 × 10–5 , MLS > 3.6)
6q25 IDDM5; ESR1 Confirmed (P < 2.2 × 10–5 , MLS > 3.6)
18q21 IDDM6  
2q31 IDDM7; IL1, HOXD8 Suggestive (P < .001, MLS > 2.2) 
6q27 IDDM8; IGF2R Confirmed (P < 2.2 × 10–5 , MLS > 3.6)
3q21-q25 IDDM9  
10p11.2-q11.2 IDDM10  
14q24.3 IDDM11 Significant (P < 2.2 × 10–5 , MLS > 3.6) 
2q33 IDDM12; CTLA-4  
2q34 IDDM13; IGFBP2, 
IGFBP5 
 
6p21 IDDM15 (distinct from HLA)  
10q25 † IDDM17 Significant (NPL: P < .002) 
7p Not assigned; GCK, IGFBP1, 
IGFBP3 
 
Xq Not assigned  
Xp ‡ Not assigned Significant (P = 2.7 × 10–4 ; MLS > 3.6) 
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Chromosome Locus 
Linkage Status According to Kruglyak & 
Lander] 
Table 3 Continued    
1q § Not assigned Suggestive (MLS = 3.31) 
HLA = human leukocyte antigen; MLS = maximum logarithm of odds score; NPL = nonparametric 
linkage; VNTR = variable number of tandem repeats. 
 
*The insulin-dependent diabetes mellitus nomenclature is assigned to a locus after linkage has been formally 
demonstrated, replicated, and confirmed in ≥3 different data sets. Where functional candidate genes are flanked by 
or are very close to susceptibility markers, they are so indicated. 
†The evidence for linkage increased substantially (P = .00004) with higher marker density and the inclusion of data 
for additional affected relatives and all unaffected siblings. 
‡In major histocompatibility complex HLA-DR3-positive patients. 
§This locus co-localizes with loci for systemic lupus erythematosus and ankylosing spondylitis. 
 
 
 
The following is a description of three additional genes that besides the HLA region, 
have shown the most reproducibility and effect on T1D risk. The insulin (INS) gene region 
located on chromosome 11p15.5 is believed to be the second major susceptibility locus for T1D 
in Caucasians. This region is also known as IDDM2. The associations with risk are with the 
region outside of the coding region, approximately 596 bp upstream of the translational start site, 
which contains variable number of tandem repeats (VNTR). At this locus there are two common 
alleles, a shorter class I allele (20-63 repeats) and a longer class III allele (140-210 repeats). It is 
the former that is associated with T1D susceptibility with class I homozygosity conferring the 
highest risk for TID. Conversely, the class III alleles have been associated with dominant 
protection. Of important note, as these areas are also highly polymorphic not all class I alleles are 
related to susceptibility and not all class III alleles act as protectants. In addition, the roles of the 
polymorphisms vary by ethnic group. Also, there have been contradictory studies that discuss the 
possibility of a relationship between the Ins gene and HLA-DQ. 
Reasons for the VNTR associations are not completely known, however they are believed 
to have a function related to how insulin mRNA is expressed in the thymus. The protective class 
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III alleles generate higher levels of insulin mRNA than do class I alleles. It is believed that 
higher levels of insulin mRNA in the thymus may support the efficient deletion of autoreactive T 
cells that are specific to the protein. Therefore, this may allow for the individual to have a higher 
immune tolerance to a key autoantigen that is associated in the pathogenesis of T1D. In contrast, 
the highest susceptibility combination of being homozygous for the class I alleles is believed to 
be explained by the fact that these alleles are believed to play a role in complete silencing of 
insulin transcripts in the thymus and thus results in the predisposition to T1D [6, 13]. 
The cytotoxic T lymphoctye antigen-4 (CTLA-4) gene is another locus that has been 
recently been associated with the risk of TID. This region is also known as IDDM12 and is 
located on chromosome 2q33. A possible mechanism of the CTLA-4 gene and T1D susceptibility 
is that it codes for an antigen that is expressed on activated T cells and is an important factor in T 
cell regulation. However, most associations have been weak and studies are still being performed 
to determine the extent of its relationship to susceptibility to TID [18]. 
A fourth gene has also shown associations for the risk to develop T1D, the LYP 
(PTPN22) gene. This gene is one of the protein tyrosine phosphatases that modulates T cell 
activation. It is believed that the LYP-Trp 620 allele is associated with T1D susceptibility as it 
results in T cell activation via a gain of function mechanism. It has also been associated with 
other autoimmune disorders including rheumatoid arthritis and lupus erythematosus. However, 
this association has only been seen in Caucasian populations [18].  
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2.5 ENVIRONMENTAL FACTORS 
A variety of factors support the fact that environmental factors are necessary for the development 
of T1D including a low MZ twin concordance rate (20-40%), T1D epidemics occurring in 
different areas of the world, and differing rates of diabetes in inbred diabetic-prone mice. These 
environmental factors have not completely determined but studies have lent evidence for 
infectious agents, toxins, and diet [16, 17].  
Viruses are one of the more well studied environmental factors believe to play a role in 
the development of T1D. They are believed to have a variety of roles including initiation, 
acceleration, or precipitation via either direct or indirect mechanisms. These mechanisms 
include, but are not limited to, directly causing diabetes by attacking and destroying the β cells, 
or initiating the autoimmune response associated with T1D. The latter can occur due to 
molecular mimicry or ‘bystander’ autoimmune activation. Molecular mimicry is when a 
particular antigen is similar to the proteins in the body, which causes an autoimmune reaction 
that is mediated by "cross reactive" T cells and/or circulating antibodies. When this occurs, the T 
cells will then destroy both the virus and the β cells during the process[19]. Bystander 
autoimmune activation occurs when inflammatory cytokines are released into the system due to 
the infection caused by the virus. Enteroviruses, such as Coxsackie B, have particularly gained 
support in relation to the development of T1D. The role of the Coxsackie B virus has been 
suggested to be related to the development of autoimmunity and thus accelerating the prediabetes 
progression stage of autoantibody development. Alternatively, it has been seen in diabetic prone 
mice that β cell specific toxins, vitamin D3 and nicotinamide, can provide varying degrees of 
protection against the development of T1D [13, 17]. 
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Infant feeding practices were first discussed as a risk factor in 1984 following a 
Scandinavian study that showed an increase in the incidence of T1D in the years where 
breastfeeding was not as common compared to years where it was. From this observation, it was 
surmised that either the absence of breastfeeding or the presence of cow’s milk was related to an 
increased risk to develop T1D. Since then, there have been many studies trying to prove or 
disprove this link. Studies on rodent diet and the subsequent development of T1D suggest that 
the risk of diabetes is increased when early weaning from breastfeeding to a diet containing 
cow’s milk proteins. As further support for the relevance of cow’s milk and the development of 
T1D is that many children with T1D have an increased production of antibodies to cow’s milk 
proteins. These studies also have placed an emphasis on the diet early in life, such as the early 
introduction of cow’s milk (less than 3 months of life) with or without the use of breastfeeding. It 
is also important to note that many studies have been performed in those considered to be 
genetically at-risk, such as the Finnish Diabetes Prediction and Prevention (DIPP) Study and 
currently the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study. This further lends 
support to the pathogenic theory of a genetically-susceptible situation that requires multiple 
environmental (viral, dietary, etc) insults for the development of the disease[3, 20]. 
It is important to note that the mechanisms for these interactions are still not completely 
known. Also, even with the animal and human data that we do have that supports these 
environmental interactions, it is also known that the highest T1D incidence in animals is in 
diabetic-prone rodents where the amount of infectious agents is lowest and where the young are 
exclusively breastfed [17]. Therefore, there is still a lot left to be desired in relation to our 
understanding of the pathogenesis of T1D. 
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2.6 AUTOANTIBODIES 
Over thirty years ago, the presence of autoantibodies in the pancreatic islet cells was 
discovered in diabetic patients. These are called islet cell antibodies (ICA). ICA is detected by 
looking at the reactions against either frozen sections of human or rat pancreas. Previously due to 
the limited availability of human pancreatic samples, rat ICA was more often used.  In addition, 
there are three main antigens that produce autoantibodies in T1D that were discovered in the 
early 1980s, early 1990s, and mid 1990s. These are GAD65, IA-2, and insulin. 
Glutamic acid decarboxylase, with a molecular weight of 65,000, also known as GAD65 
was the first to be discovered. GAD65 is found in the islet cells of the pancreas and plays a role 
in the conversion of glutamic acid to GABA, a major inhibitory neurotransmitter. It is encoded 
by the GAD65 gene located on chromosome 10p11.  
The second antigen detected was insulinoma-associated protein 2 (IA-2). IA-2 is a 
protein tyrosine phosphatase–like molecule and the encoding gene is located on chromosome 
2q35. It is expressed in neuroendocrine tissues and is found in both the α and the β cells of the 
pancreatic islets. 
The third antigen is insulin which is localized to chromosome 11p15. Measurement of 
insulin antibodies is only accurate before insulin therapy is introduced in diabetics, as they also 
can develop antibodies to the exogenous insulin which is indistinguishable upon assay. 
The presence of these autoantibodies and their relationship to the development of 
diabetes has been extensively studied. Up to 90% of newly diagnosed diabetics have at least one 
of the three antibodies compared to just 1% of individuals in the general population. The 
statistics for the number and what type of antibodies vary with the age of onset, ethnicity, and 
duration of disease [21]. 
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With studies of first degree relatives of diabetic probands, it was realized that the 
development of autoantibodies precedes the development of diabetes and can be use as a 
predictive tool in assessing the risk to develop T1D. This process of developing autoimmunity is 
believed to begin with initial activation where the number of islet autoantigens increase and 
eventually leads to the disease state. This increasing number of autoantigens is associated with 
overexpression of cytokines and other inflammatory agents and is termed “antigen spreading” or 
“epitope spreading” (epitope referring to the T cell’s molecular code words that interacts with the 
immune system). This process sets off a sequence of events and results in autoreactivity to 
numerous autoantigens [8]. It is believed that the development of autoantibodies can precede the 
development of T1D by years and that the risk does not decrease over time [22]. 
There have been multiple studies that have estimated the risk of developing autoimmune 
diabetes in both first degree relatives and individuals from the general population based on the 
presence of multiple autoantibodies. In the Diabetes Prevention Trial (DPT-1), the presence of 2 
autoantibodies conferred a risk of 65% to develop diabetes over 5 years and the presence of 3 
conferred a risk of 100% over 5 years [23]. In the Childhood Diabetes in Finland Study Group, 
the risk was 25% in the presence of two autoantibodies and was 70% with three autoantibodies 
over 6.6 years [24]. Verge et al showed a 5 year risk estimate of 68% for two autoantibodies and 
100% for three autoantibodies [25]. In studies evaluating a 10 year follow up, the presence of 
two autoantibodies conferred a 57% risk, and three autoantibodies an 80% risk (Figures 6 and 7) 
[21].  
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 Figure 6: Risk of diabetes in First Degree Relatives in the Presence of Multiple Markers. Used with 
permission by Dr. Massimo Pietropaolo. Found in Pietropaolo, M., et al., Progression to insulin-requiring 
diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes. Diabetologia, 2002. 
45(1): p. 66-76.  [26] 
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Figure 7: Risk of Diabetes for First Degree Relatives in the Presence of Multiple Autoantibodies 
(GAD65, Insulin, and IA2) [21] 
 
2.7 THE SSOP METHOD 
Before the discovery of recombinant DNA technology, HLA typing was performed by 
evaluating serologic HLA antigen responses to the introduction of sera containing Class I and II 
protein antibodies. In addition, polymorphisms in Class II proteins were analyzed by T-cell 
responses in the Mixed Lymphocyte Reaction (MLR) [27]. In a MLR, two blood samples are 
mixed together. If the individuals have different alleles, then their lymphocytes will stimulate 
each other to proliferate whereas if the have the same there will be no proliferation [28].  
Once polymerase chain reaction (PCR) techniques became readily available, they were 
employed in HLA typing. First described in the 1980s, sequence specific oligonucleotide probes 
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can now be used. This process utilizes PCR to first amplify the DNA which can then be 
hybridized with the probes that contain known specific sequences of oligonucleotides. This 
allows for identification of specific HLA alleles, which the probes hybridize to when present. 
There have been variations with the process, such as using radioactive labeling for the probes 
which is now being replaced with fluorescent dyes or enzymes[27].  
2.8 SPECIFIC AIMS 
Specific Aim 1: What is the distribution of the HLA-DQ alleles in the Type 1 diabetic population 
enrolled in the “Epidemiology and Etiology of Type 1 Diabetes” study compared to the 
literature? 
Hypothesis 1: As our population has been evaluated before and is representative of other 
populations with similar incidence rates and demographics, this study will continue to support 
the role of the HLA-DQ molecule and its specific alleles and haplotypes in the development of 
type 1 diabetes. 
Plan 1: Analyze the genetic makeup for each proband as determined by SSOP and code it 
for the number of non-Asp alleles and the presence of the DQ2 and/or DQ8 haplotypes. 
 
Specific Aim 2: What is the distribution of the HLA-DQ alleles in the first degree relatives 
enrolled in the “Epidemiology and Etiology of Type 1 Diabetes” study? 
Hypothesis 2: The first degree relative population has not been studied before in 
Pittsburgh, but should be representative of other studies performed on a demographically similar 
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population. The FDR population should also show significant differences in the distribution of 
the DQ molecule as compared to diabetic probands and unaffected unrelated controls. 
Plan 2: Analyze the genetic makeup for each first degree relative as determined by SSOP 
and code it for the number of non-Asp alleles and the presence of the DQ2 and/or DQ8 
haplotypes. 
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3.0  MATERIALS AND METHODS 
3.1 STUDY POPULATION 
The study population are subjects enrolled in the Children’s Hospital of Pittsburgh based study 
“The Etiology and Epidemiology of Type 1 Diabetes”  with the current subtitle of AGS (Antigen 
Spreading) under the direction of Dr. Dorothy Becker. The probands (also known as new onsets) 
in the study are defined as children age 1 through 18 diagnosed with diabetes mellitus, 
discharged from the hospital on insulin treatment, had a blood draw for HLA-DQ typing, and 
had their first study blood draw for autoantibody analysis within 100 days of diagnosis. The 
latter was done in order to capture their autoantibody status at onset of the disease, as this status 
is believed to change over time. In addition, it enables the analysis for insulin autoantibody 
analysis, since this measurement is not accurate once exogenous insulin treatment has been 
started. All individuals with secondary diabetes were excluded. The probands in the study were 
recruited from January 2004 until December 2006. As mentioned, 14 of the subjects were part of 
the original study (also known as called JOD) and these individuals were recruited between 
January 1980 and November 2003.  
The first degree relatives (FDRs) in the study were recruited in the same time frame and 
in order to be eligible they must be from 1 to 45 years in age, not insulin dependent diabetics at 
time of enrollment, had a blood draw for HLA-DQ typing and was a first degree relative (parent, 
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sibling, or child) of an insulin dependent diabetic child. The child with diabetes in their actual 
family did not necessarily need to be enrolled in the study. 
3.2 HLA-DQ TYPING BY REVERSE SSOP 
Genomic DNA samples were extracted from either heparinized blood samples with 
phenol/chloroform or from dried blood spots on filter paper cards. HLA typing for DQA1 and 
DQB1 alleles was performed on all subjects by PCR and hybridization with sequence specific 
oligonucleotide probes (SSOP).  
DNA extraction and purification is initially performed using the QIAmp DNA Mini and 
QIAmp Blood Mini Kit. HLA-DQ typing by SSOP is performed using Luminex™ / One Lambda 
LABType™RSSO. The procedure follows as described by the protocol. The method involves the 
use of Luminex™ microspheres that are incorporated with infrared and red dyes, which gives 
each microsphere a unique spectral address allowing for 100 different classifications of beads. 
Each classification of bead then is bound with a particular oligonucleotide probe. PCR is then 
performed to amplify the DNA samples using primers that are biotinylated. After amplification, 
the PCR products are hybridized with a mixture of microspheres that have a predetermined set of 
oligonucleotide probes bound to them. Next, the PCR product finds complimentary sequences 
and binds with the probe (bead) they recognize. Individual sample reactions are then washed to 
remove any unbound PCR product. Samples are then stained with R-Phycoerytherin-Conjugated 
Streptavidin (SAPE), which will bind to the biotinylated primer, and processed through a 
Luminex™ flow analyzer. The fluorescent intensity of PE (Phycoerytherin) on each microsphere 
classification is translated into a positive or negative reaction. The assignment of HLA typing is 
 28 
based on the reaction pattern and analyzed using the current HLA sequence data. Analysis of the 
results is performed using One Lambda LABType Visual Software. 
Any samples that were indicated as DQB1*06 alleles from the reverse SSOP method 
were further resolved using sequence specific primers (SSP) using the Dynal AllSet™ SSP 
Procedure. The SSP method is also a PCR-based method but has a higher resolution than SSOP. 
SSP was used in the case of a DQB1*06 result because it is important to identify the presence of 
the DQB1*0602 allele, as it is associated with protection from the development of T1D. 
 
3.3 DQ RISK ALLELES AND HAPLOTYPE STRATIFICATION 
The HLA-DQ results were stratified by both non-Asp status and the presence of the DQ2 and 
DQ8 haplotypes. For non-Asp status, each of the probands and FDRs were assessed for the 
presence of one, two, or zero non-Asp alleles. In addition, for those with one non-Asp allele the 
presence of *0602 on the other DQB1 allele was recorded separately as Non-Asp/0602. Having 
no non-Asp alleles is recorded as Asp/Asp. Alleles were considered to be either Asp or non-Asp 
based on the protocol of the Children’s Hospital of Pittsburgh Histocompatibility Center as 
determined in July 2005. In addition, each of the probands and FDRs were analyzed for the 
presence of the DQ2 (DQA1*0501-DQB1*0201) and DQ8 (DQA1*0301-DQB1*0302) 
haplotypes. For each individual, it was recorded if there was one (DQ2/X) or two (DQ2/DQ2) 
copies of the DQ2 haplotype, one (DQ8/X) or two (DQ8/DQ8) copies of the DQ8 haplotype, or 
for the DQ2/DQ8 genotype.  
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3.4 STATISTICAL METHODS 
The data was analyzed using Statistical Analysis System (SAS, Cary, NC, USA) software using 
a Windows operating system. Chi squared analysis was used to compare the proportions of the 
various studied groups.  
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4.0  RESULTS 
4.1 PROBANDS AND FIRST DEGREE RELATIVES (FDRS) 
4.1.1 Demographics 
For the HLA-DQ analysis there were samples from 265 probands and 1000 first degree 
relatives (FDRs). Of these, 14 of the probands were enrolled prior to February 2004 through the 
continuous original study of Etiology and Epidemiology of T1D whereas the other 251 were part 
of the Antigen Spreading Branch of the original grant that was approved for February 2004. Four 
of the probands were part of a multiplex family, all of which had a sibling also diagnosed with 
T1D. In all of the cases, only one sibling was included in the study and therefore in our analysis 
group. Tables 4-6 show the distribution of gender, race, and ethnicity for the two groups. 
Table 4: Gender Distribution for Probands and FDRs 
 
Gender Proband Count  Proband Percent (%) FDRs Count FDRs Percent (%) 
Male 151  56.98 390 39.00 
Female 112 42.26 598 59.80 
Unknown 2 0.75 12 1.20 
Total 265 100 1000 100 
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Table 5: Race Distribution for Probands and First Degree Relatives (FDRs) 
 
RACE PROBAND 
COUNT  
PROBAND PERCENT 
(%) 
FDRs 
COUNT 
FDRs PERCENT 
(%) 
White 243 91.70 871 87.1 
Black 14 5.28 27 2.70 
Other, including 
multiple races 
5 1.89 3 0.30 
Unknown 3 1.13 99 9.90 
Total 265 100 1000 100 
 
 
Table 6: Ethnicity Distribution for Probands and First Degree Relatives (FDRs) 
 
ETHNICITY PROBAND 
COUNT 
PROBAND 
PERCENT (%) 
FDRs COUNT FDRs PERCENT 
(%) 
Not Hispanic 114 43.02 604 60.40 
Hispanic 3 1.13 4 0.40 
Unknown 148 55.85 392 39.2 
Total 265 100 1000 100 
 
 
4.1.2 Non-Asp 57 Analysis for Probands and FDRs 
For the first part of the HLA-DQ analysis, individuals were classified by their non-Asp 
status as determined by the presence of 0, 1, or 2 non-Asp alleles and for the presence of 1 non-
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Asp allele in combination with DQB1*0602. Twenty-four of the probands and 77 of the FDRs 
were unable to be determined and will require HLA-DQ typing by SSP for a more detailed 
analysis of the alleles. The results for all subjects are shown in Table 7, broken by the 
relationship to the probands (parent or full sibling only) in Table 8, and the same for Caucasian 
subjects only in Tables 9 and 10.  
 
 
Table 7: Non-Asp Analysis of Probands and FDRs 
ALL SUBJECTS 
Non-Asp Status 
Frequency 
Percent 
Row Pct 
Col Pct Probands FDR Total 
Unknown 0
0.00
0.00
0.00
2
0.17
100.00
0.21
2
0.17
ASP/ASP 8
0.68
9.52
3.31
76
6.47
90.48
8.15
84
7.15
Non-ASP/ASP 74
6.30
15.51
30.58
403
34.30
84.49
43.19
477
40.60
Non-ASP/Non-ASP 154
13.11
32.77
63.64
316
26.89
67.23
33.87
470
40.00
Non-ASP/0602 6
0.51
4.23
2.48
136
11.57
95.77
14.58
142
12.09
Total 242
20.60
933
79.40
1175
100.00
Frequency Missing = 99 
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Table 8: Non-Asp 57 Analysis of Probands and FDRs, by Relationship 
 
ALL SUBJECTS 
  
Non-Asp Status 
Frequency 
Percent 
Row Pct 
Col Pct Probands
FDR: 
parent
FDR: 
sibling Total 
Unknown 0
0.00
0.00
0.00
0
0.00
0.00
0.00
2
0.18
100.00
0.65
2 
0.18 
 
 
ASP/ASP 8
0.73
10.00
3.31
40
3.63
50.00
7.22
32
2.90
40.00
10.42
80 
7.25 
 
 
Non-ASP/ASP 74
6.71
16.52
30.58
249
22.57
55.58
44.95
125
11.33
27.90
40.72
448 
40.62 
 
 
Non-ASP/Non-ASP
154
13.96
35.00
63.64
181
16.41
41.14
32.67
105
9.52
23.86
34.20
440 
39.89 
 
 
Non-ASP/0602 6
0.54
4.51
2.48
84
7.62
63.16
15.16
43
3.90
32.33
14.01
133 
12.06 
 
 
Total 242
21.94
554
50.23
307
27.83
1103 
100.00 
Frequency Missing = 171 
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 Table 9: Non-Asp 57 Analysis of Caucasian Probands and FDRs 
 
CAUCASIAN SUBJECTS 
Non-Asp Status 
Frequency 
Percent 
Row Pct 
Col Pct Probands FDR Total 
Unknown 0
0.00
0.00
0.00
1
0.10
100.00
0.12
1
0.10
ASP/ASP 7
0.68
9.46
3.14
67
6.47
90.54
8.24
74
7.14
Non-ASP/ASP 70
6.76
16.91
31.39
344
33.20
83.09
42.31
414
39.96
Non-ASP/Non-ASP 142
13.71
33.49
63.68
282
27.22
66.51
34.69
424
40.93
Non-ASP/0602 4
0.39
3.25
1.79
119
11.49
96.75
14.64
123
11.87
Total 223
21.53
813
78.47
1036
100.00
Frequency Missing = 85 
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Table 10: Non-Asp 57 Analysis of Caucasian Probands and FDRs, by Relationship 
 
CAUCASIAN SUBJECTS 
Non-Asp Status 
Frequency 
Percent 
Row Pct 
Col Pct Probands
FDR: 
parent
FDR: 
sibling Total 
Unknown 0
0.00
0.00
0.00
0
0.00
0.00
0.00
1
0.10
100.00
0.36
1 
0.10 
 
 
ASP/ASP 7
0.71
9.72
3.14
37
3.73
51.39
7.52
28
2.82
38.89
10.11
72 
7.26 
 
 
Non-ASP/ASP 70
7.06
17.46
31.39
215
21.67
53.62
43.70
116
11.69
28.93
41.88
401 
40.42 
 
 
Non-ASP/Non-ASP 142
14.31
35.41
63.68
164
16.53
40.90
33.33
95
9.58
23.69
34.30
401 
40.42 
 
 
Non-ASP/0602 4
0.40
3.42
1.79
76
7.66
64.96
15.45
37
3.73
31.62
13.36
117 
11.79 
 
 
Total 223
22.48
492
49.60
277
27.92
992 
100.00 
Frequency Missing = 129 
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4.1.3 DQ2 and DQ8 Analysis for Probands and FDRs 
In the second part of the HLA-DQ analysis, individuals were classified as having 0 
(X/X), 1 (DQ2/X) or (DQ8/X), or 2 (DQ2/DQ2) or (DQ8/DQ8) copies of the DQ2 or DQ8 
haplotypes. Also, individuals with the DQ2/DQ8 heterozygous genotype were classified as such. 
The results for all subjects are shown in Table 11, broken by the relationship of the FDR to the 
proband (parent or full sibling only) in Table 12, and the same for Caucasian subjects only in 
Tables 13 and 14. 
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 Table 11: DQ2 and DQ8 Analysis of Probands and FDRs 
ALL SUBJECTS 
DQ2 and DQ8 Status
Percent
Row Percent
Column Percent Probands FDRs Total
X/X 56
4.43
15.05
21.13
316
24.9
84.9
31.60
372
29.41
DQ2/X 59
4.66
16.67
22.26
295
23.33
83.33
29.50
354
27.98
DQ2/DQ2 17
1.34
39.53
6.42
26
2.06
60.48
2.60
43
3.40
DQ8/X 75
5.93
21.43
28.30
275
21.74
78.57
27.50
350
27.67
DQ8/DQ8 13
1.03
35.14
4.91
24
1.90
64.86
2.40
37
2.92
DQ2/DQ8 45
3.56
41.28
16.98
64
5.06
58.72
6.40
109
8.62
Total 265
20.95
1000
79.05
126
100.0
Frequency Missing = 9 
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Table 12: DQ2 and DQ8 Analysis of Probands and FDRs, by Relationship 
 
ALL SUBJECTS 
DQ2 and DQ8 Status
Frequency 
Percent 
Row Pct 
Col Pct 
Probands
 
 
FDR: 
Parent 
 
FDR: 
Sibling
 
Total 
 
 
X/X 56
4.72
16.23
21.13
181
15.25
52.46
30.32
108
9.10
31.30
33.23
345 
29.06 
 
 
DQ2/X 59
4.97
17.93
22.26
185
15.59
56.23
30.99
85
7.16
25.84
26.15
329 
27.72 
 
 
DQ2/DQ2 17
1.43
43.59
6.42
14
1.18
35.90
2.35
8
0.67
20.51
2.46
39 
3.29 
 
 
DQ8/X 75
6.32
22.39
28.30
173
14.57
51.64
28.98
87
7.33
25.97
26.77
335 
28.22 
 
 
DQ8/DQ8 13
1.10
37.14
4.91
11
0.93
31.43
1.84
11
0.93
31.43
3.38
35 
2.95 
 
 
DQ2/DQ8 45
3.79
43.27
16.98
33
2.78
31.73
5.53
26
2.19
25.00
8.00
104 
8.76 
 
 
Total 265
22.33
597
50.29
325
27.38
1187 
100.0
0 
Frequency Missing = 87 
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Table 13: DQ2 and DQ8 Analysis of Caucasian Probands and FDRs 
 
CAUCASIAN SUBJECTS 
DQ2 and DQ8 Status
Frequency 
Percent 
Row Pct 
Col Pct Probands FDR Total 
X/X 51
4.58
15.74
20.99
273
24.51
84.26
31.34
324
29.08
DQ2/X 54
4.85
17.25
22.22
259
23.25
82.75
29.74
313
28.10
DQ2/DQ2 14
1.26
37.84
5.76
23
2.06
62.16
2.64
37
3.32
DQ8/X 69
6.19
22.77
28.40
234
21.01
77.23
26.87
303
27.20
DQ8/DQ8 13
1.17
35.14
5.35
24
2.15
64.86
2.76
37
3.32
DQ2/DQ8 42
3.77
42.00
17.28
58
5.21
58.00
6.66
100
8.98
Total 243
21.81
871
78.19
1114
100.00
Frequency Missing = 7 
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Table 14: DQ2 and DQ8 Analysis of Caucasian Probands and FDRs, by Relationship 
 
CAUCASIAN SUBJECTS 
DQ2 and DQ8 Status
Frequency 
Percent 
Row Pct 
Col Pct Probands
FDR: 
parent
FDR: 
sibling Total 
X/X 51
4.78
16.56
20.99
161
15.10
52.27
30.43
96
9.01
31.17
32.65
308 
28.89 
 
 
DQ2/X 54
5.07
18.00
22.22
167
15.67
55.67
31.57
79
7.41
26.33
26.87
300 
28.14 
 
 
DQ2/DQ2 14
1.31
41.18
5.76
13
1.22
38.24
2.46
7
0.66
20.59
2.38
34 
3.19 
 
 
DQ8/X 69
6.47
23.47
28.40
147
13.79
50.00
27.79
78
7.32
26.53
26.53
294 
27.58 
 
 
DQ8/DQ8 13
1.22
37.14
5.35
11
1.03
31.43
2.08
11
1.03
31.43
3.74
35 
3.28 
 
 
DQ2/DQ8 42
3.94
44.21
17.28
30
2.81
31.58
5.67
23
2.16
24.21
7.82
95 
8.91 
 
 
Total 243
22.80
529
49.62
294
27.58
1066 
100.00 
Frequency Missing = 55 
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5.0  DISCUSSION 
5.1 PROBANDS  
5.1.1 Non-Asp 57 Analysis of Probands Compared to Probands in the Literature 
Looking at the presence of non-Asp in the probands, 96.65% have at least one non-Asp 
allele, including the individuals with non-Asp plus DQB1*0602 (DR2) which is a protective 
haplotype. Not including the DR2 group, 94.14% have at least one non-Asp allele with a 
breakdown of 30.54% with one non-Asp allele and 63.60% with two non-Asp alleles. For this 
analysis, we will combine the DQB*0602 individuals with the non-Asp/Asp group as in the 
Dorman et al. 1990 study, they did not differentiate between the presence of the 0602 allele. 
Therefore, our estimates for one non-Asp is 33.05% and for two non-Asp alleles is 63.60% 
compared to the Dorman estimates of 33% and 70% respectively. Looking at just the Whites in 
this study, 33.18% had one non-Asp allele and 63.68% had two non-Asp alleles. This is 
compared to approximately 33% and 61%, respectively, in the Dorman study (Table 15). 
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Table 15: Comparison of Non-Asp Status in Caucasians to Previous Literature on Diabetics 
 
STUDY 
POPULATION 
Caucasian Diabetics 
(Probands)—Smolnik  
Caucasian Diabetics—Dorman 
et al.  
Total 
Non-Asp/Non-Asp 142 (63.68%) 30 (61.22%) 172 
Non-Asp/Asp 74 (33.18%) 19 (32.65%) 93 
Asp/Asp 7 (3.17%) 0 (0%) 7 
Total 223 49 316 
 
 
While the differences between the two non-Asp/non-Asp groups are not significant (chi 
squared test p-value is approximately 0.975), they may be related to the age differences in the 
two studies. In the Dorman study, the age at diagnosis in the diabetic population was less than 
15, whereas in our study 9.27% of the subjects were diagnosed over the age of 15. This may be 
important as typically the higher risk haplotypes are associated with younger ages of onset. Since 
we have individuals with older ages of onset, they may contribute to the overall lower numbers 
of higher risk haplotypes. Also, this study’s population includes some individuals of other or 
multiple races whereas the Dorman study includes Blacks and Whites only. In addition, while 
unlikely the fact that in the Dorman study HLA-typing was performed by Dot blot analyses with 
DQBI allele specific oligonucleotide probes whereas in our study we use a more current and 
specific technology of reverse sequence specific oligonucleotide probes may contribute some 
small differences [29]. 
Seven of the 221 Caucasian probands (3.17%, 3.35% for entire population) had two Asp 
alleles at position 57 of the DQ beta chain. Again, this lower incidence is to be expected as it is 
the presence of non-Asp alleles that are associated with the risk of developing T1D. In the 
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Dorman study of Caucasian probands, 0% were Asp/Asp. Other studies have found incidences of 
0% as well [30]. In evaluating these higher than expected results, it was noted that 2 of the 7 
Asp/Asp individuals reports themselves as Hispanic (also 2 of the 3 Hispanics in our population) 
and some studies have suggested that the presence of Asp-57 does not confer protection in the 
Mexican-American ethnic group [31]. In addition, one of Asp/Asp individuals upon further 
review of medical records most likely has Type 2 diabetes. He was diagnosed at 17 years, is 
overweight, has acanthosis and high blood pressure, and did not present classically with diabetic 
ketoacidosis. This patient was discharged on insulin but has subsequently been switched to oral 
medications. Another one of the individuals is a female diagnosed at 5 years, no diabetic 
ketoacidosis, overweight, and is suspected to have either T1D or double diabetes. In addition, 
HLA is not the only genetic loci linked to T1D, in fact accounts only for 50-60% of the genetic 
risk, and in these cases the disease may be the result of a combination of other susceptibility 
genes and environmental interactions. This is also supported by the fact that several of the 
individuals are overweight. In the situation where an individual is overweight and has T1D, it 
may be the case that obesity causes insulin resistance, requiring the body to produce more insulin 
leading to minor beta cell damage and therefore a lower or “less risky” genetic load would be 
required for disease development. In addition, it may the case in these individuals’ disease is 
related to other genes.  
The Asp/Asp individuals’ family histories were also evaluated to identify any possible 
incidences of MODY or other familial situations of the disease. Of the 7, 2 were reported to have 
a strong family history of Type 2 diabetes. One individual had a family history of thyroid 
disease. However, three had no family history of Type 1 or 2 diabetes or other endocrine 
 44 
diseases. Therefore, it may be these variations in clinical features and course as well as ethnicity 
that can be attributed to the higher incidence Asp/Asp homozygotes found in this study. 
Multiple studies both in the United States and Europe, such as Hermann et al [32], have 
shown that less than 1% of children with type 1 diabetes are DR2 (DQB1*0602). Our study 
shows about double this amount with 6 of our 239 (2.51%) with the DQA1*0101-DQB1*0602 
haplotype that has been associated with near absolute protection from developing T1D [33]. This 
theory of absolute protection has been disproved before, as in Pugliese et al where 6 children 
with T1D had the normal DQB1*0602 and DQA1*0102 [15]. In the Swedish Childhood 
Diabetes Study Group and The Diabetes Incidence in Sweden Study (DISS) Group the haplotype 
was absent before the age of 10 but the incidence increased with later ages of onset [34]. This is 
consistent as in our study 4 of the 6 were diagnosed at or over the age of 10 (ages of diagnosis 
for all six were 5, 8, 10, 10, 13, and 14).  
These individuals’ family histories were also examined. One individual has a maternal 
great grandmother with T1D, a mother with hyperthyroidism, and a maternal grandfather with 
Crohn’s disease. Another individual’s maternal history was only available. This includes an 
uncle and grandmother with non-insulin dependent diabetes with the grandmother also having 
hypothyroidism. Another person had a strong maternal and paternal family history of type 2 
diabetes. The fourth person has a strong family history of thyroid disease and type 2 diabetes. 
The fifth individual has late onset diabetes in the maternal grandparents, with the grandmother 
also having hypothyroidism. Her father’s history is significant for celiac disease. The last 
individual has a family history of diabetes mellitus in her maternal aunt and paternal great 
grandmother. It is important to recognize that all of these individuals have a family history of 
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either diabetes or an autoimmune condition, as this may suggest that there are other genetic and 
environmental factors playing a role in their case of T1D. 
It is also of interesting note that upon review of their medical history, 3 of the 6 
individuals with the DQB1*0602 haplotype are suspected to have what is known as type 1.5 
diabetes or double diabetes. Double diabetes is when an individual has signs of both autoimmune 
diabetes and insulin resistance. There is, however, no published information about the 
relationship between HLA-DQ alleles and double diabetes. 
5.1.2 Non-Asp 57 Analysis of Probands Compared to Unaffected Individuals 
Our results show that the distribution of non-asp alleles in our probands and FDR population 
supports the multitude of studies that have shown that the presence of non-Asp at position 57 of 
DQ beta is associated with the risk of T1D. Using a chi squared test with 2 degrees of freedom to 
compare the presence of Asp 57 in the diabetic probands and their unaffected first degree 
relatives, we get a chi-squared value of 8.45 and 2 degrees of freedom we get a significant p-
value of 0.0146 (Table 16). This supports the hypothesis that role of the non-Asp alleles are 
associated with the development of T1D, as there are statistically significant higher amount of 
diabetics with two non-Asp alleles than unaffected FDRs and lower amounts of diabetics with 
only one non-Asp allele or two Asp alleles.  
Table 16: Comparison of Non-Asp Status for Caucasian Probands vs. FDRs 
 
Study Population Caucasian Diabetics (Probands) Caucasian FDRs  Total 
Non-Asp/Non-Asp 142 (63.68%) 282 (34.73%)  424 
Non-Asp/Asp 74 (33.18%) 463 (57.02%) 537 
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Table 16 Continued    
Asp/Asp 7 (3.17%) 67 (8.25%) 74 
Total 223 812 1035 
 
If you compare this study’s probands to the general population statistics in Dorman et al. 
you will see again that again there is a difference in the presence of non-Asp alleles in the two 
populations which supports the role of non-Asp in T1D susceptibility. In the Dorman study, the 
individuals in the general population group were unrelated non-diabetic controls. This 
information is presented in Table 17 below and the differences are statistically significant with a 
chi squared value of 11.09 and 2 degrees of freedom gives us a p-value of 0.0039. 
  
Table 17: Comparison of Non-Asp Status in Caucasian Probands and General Population in the 
Literature 
 
STUDY 
POPULATION 
Caucasian Diabetics 
(Probands)—Smolnik  
Caucasian General Population—
Dorman et al.  
Total 
Non-Asp/Non-Asp 140 (63.35%) 24 (19.51%)  164 
Non-Asp/Asp 74 (33.48%) 57 (46.34%) 131 
Asp/Asp 7 (3.17%) 42 (34.15%) 49 
Total 221 123 344 
 
In addition, if further compare the probands to the FDRs and also to the general 
population (Table 18), you can see that as described before, the percentages follow the role of 
non-Asp alleles in T1D risk. This is illustrated by the fact that the majority of probands are non-
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Asp/non-Asp, FDRs have one non-Asp allele, and individuals in the general population have 
mostly either one non-Asp or are Asp/Asp. 
 
 
 
Table 18: Caucasian Analysis: Probands vs. FDRs vs. General Population 
 
STUDY 
POPULATION 
Caucasian Diabetics 
(Probands)—Smolnik 
Caucasian FDRs--
Smolnik 
Caucasian General Population—
Dorman et al.  
Non-Asp/Non-Asp 140 (63.35%) 282 (34.69%) 24 (19.51%)  
Non-Asp/Asp 74 (33.48%) 463 (56.95%) 57 (46.34%) 
Asp/Asp 7 (3.17%) 67 (8.24%) 42 (34.15%) 
Total 221 812 123 
 
5.1.3 DQ2 and DQ8 Distribution of Probands 
In regard to the DQ2 and DQ8 haplotype analysis our results show that 78.63% of the 
probands possessed DQ2 and/or DQ8 haplotypes. This includes all races and ethnicities. If you 
evaluate Caucasian probands only, 78.83% possessed the DQ2 and/or DQ8 haplotypes. This is 
lower than several other studies which have shown an estimates of >90-95% [12, 30]. In the 
breakdown, 6.49% were DQ2 homozygotes (DQ2/DQ2), 4.96% were DQ8 homozygotes 
(DQ8/DQ8), and 16.79% were DQ2/DQ8 heterozygotes. If you only look at the Caucasian 
probands the breakdown is 5.81%, 5.39%, and 17.01%. Again, these estimates are lower than 
other study results. For example, the IX International Histocompatibility Workshop in 1984 
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found the haplotypes for Caucasian type 1 diabetics to be 7.2% DR3 homozygous, 7.9% DR4 
homozygous, and 33.6% DR3/DR4 heterozygous respectively [12]. In addition, other studies 
have shown estimates of 30–50% of patients to be DR3/DR4 (DQ2/DQ8) heterozygotes [18, 23]. 
While our study looks at DQ and these other studies are analyzing DR, the numbers should be 
comparable due to the high LD between the two loci.  
One issue of the differences in the numbers may be due to the fact that the DR3/DR4 
statistics are typically higher in diabetics diagnosed under the age of five. The original statistics 
on the age of diagnosis of the diabetics in those studies were not available for review; however 
an analysis was still performed on the diabetic probands in this study to see if the estimates are 
similar to other studies looking at groups in this age at diagnosis range. Of our Caucasian 
probands, 34 (13.13%) were less than five years at the age at diagnosis. Of these 34, 3 of them 
required more specific HLA analysis in order to determine the presence of either the DQ2 or 
DQ8 haplotypes or the number of non-Asp alleles. Therefore, there are 31 diabetics probands 
diagnosed under the age of 5 available for analysis. Of these, 7 were DQ2/DQ8 heterozygotes 
(22.58%). However, looking at all 40 diabetic probands that are DQ2/DQ8 heterozygotes only 7 
(17.5%) were diagnosed under the age of 5. Again, these numbers are not consistent with studies 
of those diagnosed before the age of 5 where estimates can range from 50% to ~63% [35, 36]. 
Looking at the DQ2 and DQ8 (including DQ2 and DQ8 homozygotes and heterozygotes, 
but not DQ2/DQ8 heterozygotes) frequencies separately, the diabetic probands in our study had 
frequencies of approximately 29% and of 33%, respectively. Comparing these to the frequencies 
of DR3 and DR4 among diabetic haplotypes in Allegheny County in 1988 conducted by Morel et 
al. were 29% and 48%, respectively [30]. These differences are not statistically significant with a 
chi squared value of .7893 with 2 df and p-value of 0.674 (Table 19). 
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 Table 19: Comparison of DQ2 (DR3) and DQ8 (DR4) Haplotypes in Diabetic Probands in the Study 
vs. Morel et al 
 
Study Population Diabetic Probands—
Smolnik  
Diabetic Probands—Morel et 
al. 
Total 
DQ2 76 (28.68%) 20 (28.99%)  96 
DQ8  88 (33.21%) 33 (47.83%) 121 
Other haplotypes 101 (38.11%) 16 (23.19%) 117 
Total 265 69 334 
 
Overall, the differences between the statistics in this study compared to the literature in 
relation to the DQ2 and DQ8 haplotypes are significant. As discussed before, these differences 
may be the result of other genetic loci playing a role in this particular population. However, due 
to having data available from previous populations in Allegheny County, it may be less likely 
there was any significant change in the genetic distribution of these haplotypes. Also, by 
controlling for race there are no differences associated with the differences found in race and 
ethnicity distributions. However, based on other studies which have found an increasing amount 
of obesity in this T1D population, it may be that the obesity is added strain to cause for a higher 
insulin requirement and therefore requiring less of a genetic load if you will to develop T1D.  
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5.2 FIRST DEGREE RELATIVES RESULTS 
5.2.1 Non-Asp 57 Analysis of FDRs 
In the first degree relatives, the presence of 0, 1, 2 non-Asp alleles as well as the combination of 
DQB1*0602/non-Asp was determined. Of the 1000 FDRs, 67 were unable to be determined by 
the reverse SSOP method and will need further analysis by SSP. Therefore, there was 933 FDRs 
available for the non-Asp 57 analysis. The results include approximately 34% non-Asp/non-Asp, 
58% Asp/non-Asp (with about 14.5% of these individuals non-Asp/0602 specifically), and 8% 
Asp/Asp. Compared to the diabetic probands in the study the amount of Asp/Asp, Asp/non-Asp, 
and non-Asp/0602 individuals are all higher whereas the amount of non-Asp/non-Asp 
individuals is lower. This is consistent with the risks associated with each haplotype (i.e. the 
presence of two non-Asp alleles carries the most risk to develop T1D). Also consistent with what 
we know about the genetic susceptibility of T1D, the presence of non-Asp alleles is increased, 
with the exception of Asp/Asp individual which again is to be expected, when compared to the 
general population who are unaffected and unrelated to an individual T1D. For example, in 
Dorman et al., the frequency of unaffected, unrelated controls being non-Asp/non-Asp, non-
Asp/Asp, and Asp/Asp was 20%, 46%, and 34%, respectively (Table 20) [29]. 
 
Table 20: Approximate Non-Asp Status of Caucasian Probands vs. FDRs vs. Controls in Dorman et 
al. 
Non-Asp Status Probands (%) FDRs (%) Controls-Dorman et al (%) 
Non-Asp/Non-Asp 64 34 20 
Non-Asp/Asp 33 58 46 
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Table 20 Continued    
Asp/Asp 3 8 34 
Total 100 100 100 
 
For a breakdown of the 1000 FDRs, there are 861 known individuals to be a parent or a 
full sibling, 554 and 307 respectively (Table 21). Comparing these results of non-Asp status we 
see that there are no significant differences (p-value of 0.551) between the parents and siblings. 
There is a statistically significant difference between the two FDR categories when they are 
compared to either the proband or control group. These differences are supported by the fact that 
probands should have the highest amount of risk genes, followed by FDRs as they share common 
genes with the proband and thus also have a risk to develop T1D, as well as the fact that there are 
individuals in the FDR group that will go on to later develop T1D, and with the unaffected, 
unrelated controls with the lowest amount of risk genes as they have the lowest empirical risk 
and do not share genes with an affected FDR. However, this data does not support the theory that 
since siblings more often share haplotypes with their affected proband sibling and are young 
enough to have still have a chance to develop T1D, they will have higher amounts of risk genes 
than do the parent FDRs who are in a later age group and if still unaffected, they most likely do 
not have the higher risk genes. This may be the result of a younger average age of the parents, 
which the data was unavailable at the time of analysis. If the parents were mostly younger, such 
as their twenties and not late thirties or early forties, then it may be that the risk of developing 
T1D is similar to the parent group as it is for the sibling group. It would be interesting to look at 
the autoantibody results of these two groups as well to examine any possible differences and how 
this may adjust the risk for the two groups. 
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Also, one could hypothesize that based on the theory that those with the highest risk 
genes go on to develop diabetes, then we may expect to see even less of the highest risk 
categories in the FDR parent population than in a general population group of all ages.  In the 
Dorman study however, the unaffected, unrelated controls were all adults and so such a 
comparison cannot be made with that study population. 
 
Table 21: Approximate Percentages of Non-Asp Status of Caucasian Probands vs. Siblings vs. 
Parents vs. Controls in Dorman et al. 
 
Non-Asp Status Probands (%) Siblings (%) Parents (%) Controls-Dorman et al.  (%)  
Non-Asp/Non-Asp 64 34.5 33 20 
Non-Asp/Asp 33 55.5 59 46 
Asp/Asp 3 10 8 34 
Total 100 100 100 100 
 
In regard to the presence of DQB1*0602 in first degree relatives, most studies first 
identify FDRs who are antibody-positive and then follow with DQ haplotype analysis. Therefore, 
most of the data is first stratified by antibody-positive FDRs and are therefore and not exactly 
comparable to this study since autoantibody status was unknown to this study at the time. For 
example, the Diabetes Prevention Trial-1 (DPT-1) aimed at identify relatives at risk for 
developing T1D in order to design intervention trials to prevent the disease. Through this 
process, DPT-1 identified a large cohort of antibody-positive DQB1*0602 positive relatives. Of 
their large group of 81,000 first and second degree relatives, 3.6% were antibody positive and 
offered genetic analysis. Of the antibody positive group, approximately 7.7% (n=225) first and 
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second degree relatives were identified with the 0602 allele. In this study, approximately 15% of 
parents and 14% of siblings were found to have the DQB1*0602 allele. Again, this may be 
higher because of several reasons including we are looking at just first degree relatives and that 
we are looking at all FDRs and not just FDRs who are autoantibody positive. In addition, these 
numbers for the parents and siblings are significantly different than that of the general population 
which is approximately 25% [37].  
 
5.2.2 DQ2 and DQ8 Analysis of FDRs 
For the FDRs, approximately 68% had DQ2 and/or DQ8 haplotypes, whereas fewer than 
40% of normal controls have these haplotypes [38]. Specifically, about 32% were either DQ2 
homozygotes or heterozygotes, 30% were either DQ8 homozygous or heterozygous, and 6% 
were DQ2/DQ8 heterozygotes. Evaluating the amount of DQ2/DQ8 heterozygote in the FDRs, 
we see 6% in this study compared to ~16-17% of probands in this study and 30-50% of probands 
in multiple other studies as described previously, and compared to an incidence of <1% to 3% in 
the general population [23, 39]. These results can be supported based on the role of the 
DQ2/DQ8 genotype as conferring the highest susceptibility to the disease. To be more specific, 
we would expect less FDRs to have this genotype compared to those affected with T1D. We 
would also expect there to be more FDRs than unaffected, unrelated controls in this group as 
FDRs share genes in common with affected individuals who also more often have these risk 
genes as well as FDRs have a higher risk to develop T1D than do those in the general population 
and some in this group may still go on to develop the disease. Furthermore, there were no 
significant differences (p-value of 0.401) between the DQ2 and DQ8 haplotypes between parents 
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and full siblings. Again, as discussed for the non-Asp analysis, this may be explained by if there 
is a younger average age of the parents and that some of the parents will go on to develop T1D. 
5.2.3 Future Directions 
The ultimate goal of this project is to be able to provide families that have participated in the 
“Epidemiology and Etiology of Type 1 Diabetes” research study more accurate information on 
their individual risk for developing T1D. From the many studies performed both by the research 
groups and Children’s Hospital of Pittsburgh and around the world, it has already been 
determined that specific HLA haplotypes confer a risk as well as does the presence of specific 
autoantibodies.  
The next phase of this project would entail analyzing both the probands and first degree 
relatives to determine if any one haplotype is more associated with any of the autoantibodies that 
precede the disease state. Therefore, each person would have both their genetic risk in addition to 
the risk of developing autoantibodies, which even more accurately predict the likelihood of the 
development T1D. The final phase of the project would then be to construct an appropriate 
genetic and autoimmunity education session to provide genetic counseling to these individuals at 
risk for developing T1D. There are already several pilot programs pursuing this based on an 
individual’s genetic risk alone, such as GIFT-D. Being able to provide information with even 
higher predictability, including both genetics and autoimmunity, would be more beneficial for 
the participants, as it will allow them to better know their individual risk and possibly pursue the 
intervention trials that are currently ongoing or new ones in the future. 
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6.0  CONCLUSIONS 
This study has allowed for an analysis of the HLA-DQ molecule in both a large group of 
probands and first degree relatives of affected individuals. The results for the analysis of the 
presence of non-Asp alleles in both the probands and FDRs were consistent both with the role of 
the non-Asp allele in the risk of developing T1D when comparing these groups to each and to 
unaffected, unrelated controls. Also, these results were mostly consistent with previous results in 
the literature. It was noted that the percentage of individuals with two Asp alleles was higher in 
this proband population than expected, 3% compared to multiple other studies showing 0%. 
When evaluating the individuals personal, medical, and family history we did see of some 
significance several individuals who were Hispanic, several they have a non-classical picture of 
T1D suggesting either Type 1.5 (“Double Diabetes”) or 2 diabetes, and several overweight 
individuals. These features may support a hypothesis that these individual’s disease development 
may be attributed to other susceptibility genes, as seen especially in other ethnic backgrounds, or 
that the presence of obesity may require a higher demand for insulin and thus lowering the need 
for susceptibility genes for disease development.  
In addition, as the DQB1*0602 allele is supposed to be associated with disease 
protection, we evaluated the ~2.51% probands with this haplotype. After analysis, it was 
determined that 66.67% were diagnosed after the age of 10, all had a family history of diabetes 
(either type 1 or type 2) or other autoimmune diseases, and 50% of the individuals were 
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suspected of having “double diabetes”. Again, these findings are significant in the fact that they 
represent a non-classical picture of an individual with T1D and while there is no published data 
yet available on the relationship between HLA-DQ and double diabetes there may be such an 
association in the future that we could compare this group to. 
The non-Asp analysis of the FDRs was consistent with the risks associated with each 
allele combination both when compared to probands and to unaffected, unrelated controls. When 
comparing parents versus full siblings, unexpectedly there were no significant differences. 
Again, this may be explained if there is a younger average age of the parents and that some of the 
parents will go on to develop T1D.  
When assessing the distribution of the HLA-DQ2 and DQ8 haplotypes, the percentage of 
probands who were DQ2/DQ8 heterozygous was not consistent with previous studies in the 
literature including studies that were performed previously in Allegheny County. When isolating 
this group to look at either just Caucasians or those diagnosed under the age of five there were 
still significant differences. As discussed before, these differences may be the result of other 
genetic loci playing a role in this particular population. In addition, it may be that the increasing 
decreased amount of individuals with the highest risk-conferring genotype is the result of the 
increasing amount of obese individuals, which may require a larger insulin requirement thereby 
requiring less of a genetic load to develop T1D. 
These first degree relative DQ2 and DQ8 results indicated a significant difference 
between FDRs and the risk categories including fewer individuals in the high risk groups than 
probands and more individuals than unaffected, unrelated controls. This is supported by the role 
of the DQ2/DQ8 genotype conferring the highest susceptibility to the disease. Furthermore, the 
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analysis of the differences between parents and full siblings again was not as expected as there 
were no significant differences between the DQ2 and DQ8 haplotypes.  
This study has provided several important findings as it allows for further verification of 
the role HLA plays in diabetes as well as allows for more accurate disease prediction. As 
discussed before, this project plays the initial important role of being able to provide disease risk 
assessment to research participants. As the morbididy and mortality of T1D affects our society’s 
healthcare and economy, a key to prediction and hopefully prevention will be just as important 
on the personal level as it will on a large-scale public health level. 
 
 
 
 
 
 
 
 
 
 
 
. 
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